natgillin/translations-raw huggingface dataset:
The maximum licensed dose of fluticasone propionate delivered by Seretide inhaler in children is 100mcg twice daily. 
Največji odobreni odmerek flutikazonijevega propionata, ki ga odda inhalator Seretide, je pri otrocih 100 mikrogramov dvakrat na dan.
The patient should also be medically reviewed where the current dosage of Seretide has failed to give adequate control of asthma. 
Prav tako je bolnika treba pregledati, če trenutni odmerek Seretida astme ne obvlada ustrezno.
The recommendation included in section 4.2 allows a short term trial of Seretide Evohaler in adults and adolescents with moderate persistent asthma for whom rapid control of asthma is essential. 
Priporočilo v poglavju 4.2 dovoljuje kratkotrajno preskušanje zdravila Seretide Evohaler pri odraslih in mladostnikih z zmerno perzistentno astmo, pri katerih je hiter nadzor astme nujen.
Seretide Evohaler is for inhalation use only. 
Seretide Evohaler je namenjen samo za inhaliranje.
In cases of fluticasone propionate overdose Seretide therapy may still be continued at a suitable dosage for symptom control. 
V primeru prevelikega odmerjanja flutikazonijevega propionata je mogoče terapijo s Seretidom kljub temu nadaljevati v ustreznem odmerku za obvladanje simptomov.
Only take these medicines whilst on Seretide, if told to do so by your doctor. 
Zato takšna zdravila uporabljajte hkrati s Seretidom le, če vam tako naroči zdravnik.
The possible side effects associated with Seretide are unlikely to affect your ability to drive or use machines. 
Vpliv na sposobnost upravljanja vozil in strojev Ni verjetno, da bi možni neželeni učinki, povezani s Seretidom, neugodno vplivali na vašo sposobnost upravljanja vozil in strojev.
Seretide does not work in controlling sudden attacks of breathlessness and wheezing where you would need to use your fast acting ‘rescue' medication. 
Vendar pa Seretide ne more obvladati nenadnih napadov težkega in piskajočega dihanja: v takšnem primeru morate uporabiti hitrodelujoče "olajševalno" zdravilo.
Treatment with Seretide should not be stopped abruptly. 
Terapije s Seretidom ne smete prekiniti nenadoma.
Patients should be made aware that Seretide Evohaler must be used daily for optimum benefit, even when asymptomatic. 
Bolnikom je treba pojasniti, da morajo za najboljši učinek Seretide Evohaler uporabljati vsak dan, tudi kadar nimajo simptomov.
There are no data available for use of Seretide in patients with hepatic impairment. 
Podatkov o uporabi Seretida pri bolnikih z okvaro jeter ni.
Seretide is contraindicated in patients with hypersensitivity to any of the active substances or to the excipient. 
Seretide je kontraindiciran pri bolnikih, ki so preobčutljivi za katerokoli zdravilno učinkovino ali pomožno snov.
Your doctor will supervise your treatment more closely if you have medical conditions such as heart disease including an irregular or fast heart beat, overactive thyroid gland, high blood pressure, diabetes mellitus (Seretide may increase your blood sugar), low potassium in your blood or if you are being, or have been treated for have tuberculosis (TB). 
Bodite posebno pozorni pri uporabi zdravila Seretide Zdravnik bo vaše zdravljenje spremljal natančneje, če imate kakšno zdravstveno težavo, npr. bolezen srca (vključno z nerednim ali hitrim srčnim utripom), čezmerno dejavno ščitnico, visok krvni tlak, diabetes mellitus (Seretid lahko zviša krvni sladkor), nizek kalij v krvi ali se zdravite oz. ste se zdravili zaradi tuberkuloze.
If you are using high doses of Seretide for a long time, one of the active ingredients, fluticasone propionate, may stop the natural production of steroid hormones by the adrenal gland. 
Če dolgo časa uporabljate velike odmerke Seretida, lahko flutikazonijev propionat, ki je ena od obeh zdravilnih učinkovin, zavre naravno nastajanje steroidnih hormonov v nadledvičnih žlezah.
Symptomatic candidiasis can be treated with topical antifungal therapy whilst still continuing with the Seretide Evohaler. 
Simptomatsko kandidozo je mogoče zdraviti z lokalno antimikotično terapijo ob nadaljevanju uporabe Seretide Evohalerja.
GOAL showed more patients treated with Seretide achieved asthma control than patients treated with ICS alone and this control was attained at a lower corticosteroid dose. 
Študija GOAL je pokazala, da je obvladanje simptopmov astme doseglo več bolnikov, ki so dobivali Seretide, kot bolnikov, ki so dobivali samo IKS (inhalacijski kortikosteroid) in da je bilo to obvladanje doseženo pri nižjih odmerkih kortikosteroida.
HOW TO TAKE SERETIDE 
Kako jemati zdravilo Seretide
No ICS (SABA alone) Low dose ICS ( ≤500mcg BDP or equivalent/day) Medium dose ICS (>500-1000mcg BDP or equivalent/day) Pooled results across the 3 treatment levels *Well controlled asthma; occasional symptoms or SABA use or less than 80% predicted lung function plus no night-time awakenings, no exacerbations and no side effects enforcing a change in therapy **Total control of asthma; no symptoms, no SABA use, greater than or equal to 80% predicted lung function, no night-time awakenings, no exacerbations and no side effects enforcing a change in therapy. 
brez IKS (samo KDAB) nizkoodmerni IKS ( ≤ 500 mikrogramov BDP ali ekvivalentno/dan srednjeodmerni IKS (> 500 do 1000 mikrogramov BDP ali ekvivalentno/dan) kumulativni rezultati vseh 3 ravni terapije *Dobro urejena astma: občasni simptomi ali uporaba KDAB (kratkodelujočega agonista beta) ali manj kot 80 % predvidene pljučne funkcije ter brez prebujanj ponoči, brez poslabšanj in brez neželenih učinkov, ki bi zahtevali spremembo terapije.
Glaxo SmithKline Pharma GmbH Albert Schweitzer Gasse 6 1140 Wien 
Glaxo SmithKline Pharma GmbH, Albert Schweitzer Gasse 6, 1140 Wien, Avstrija
The time on treatment for 50% of subjects to achieve a first individual Well-Controlled week was 16 days for Seretide compared to 37 days for the ICS group. 
Pri 50 % oseb je bil prvi posamezni teden z dobro nadzorovanostjo dosežen po 16 dneh zdravljenja z zdravilom Seretide oziroma po 37 dneh zdravljenja z inhalacijskim kortikosteroidom.
What Seretide looks like and contents of the pack Pressurised inhalation, suspension. 
Izgled zdravila Seretide in vsebina pakiranja Inhalacijska suspenzija pod tlakom.
Seretide Evohaler and associated names (see Annex I of Opinion) contain salmeterol and fluticasone propionate, a fixed dose combination of the long acting β-agonist (LABA) salmeterol and the inhaled corticosteroid (ICS) fluticasone propionate (FP) indicated in the regular treatment of asthma where use of a combination product (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate:patients not adequately controlled with inhaled corticosteroids and ‘as needed' inhaled short acting beta-2-agonist or - patients already adequately controlled on both inhaled corticosteroid and longacting beta-2-agonist. 
Zdravilo Seretide Evohaler in z njim povezana imena (glejte Dodatek I Mnenja) vsebujejo salmeterol in flutikazon propionat, kombinacijo fiksnih odmerkov dolgo delujočega β-agonista (LABA) salmeterola in inhalacijskega kortikosteroida (ICS) flutikazon propionata (FP), indicirano za običajno zdravljenje astme, kjer je uporaba kombiniranega izdelka (dolgo delujočega β-agonista in inhalacijskega kortikosteroida) ustrezna: - pri bolnikih, pri katerih z inhalacijskimi kortikosteroidi in »po potrebi« z inhalacijskim kratko delujočim beta-2-agonistom ni mogoče doseči zadostnega nadzora bolezni, ali - pri bolnikih, pri katerih je bilo mogoče že z inhalacijskimi kortikosteroidi in dolgo delujočim beta-2-agonistom vzpostaviti zadosten nadzor bolezni.
LIST OF EXCIPIENTS Norflurane (HFA 134a) 
SEZNAM POMOŽNIH SNOVI Norfluran (HFA 134a)
Your doctor will check you regularly for any of these side effects and to make sure you are taking the lowest dose of Seretide to control your asthma. 
Zdravnik vas bo redno kontroliral glede teh neželenih učinkov, tako da boste za obvladanje astme dobivali najmanjši odmerek Seretida.
Well-Controlled asthma was achieved more rapidly with Seretide than with ICS alone. 
Z zdravilom Seretide je bila dobra nadzorovanost astme dosežena hitreje kot z inhalacijskim kortikosteroidom samim.
CLINICAL PARTICULARS 4.1 Therapeutic indications Seretide is indicated in the regular treatment of asthma where use of a combination product (longacting beta-2-agonist and inhaled corticosteroid) is appropriate: patients not adequately controlled with inhaled corticosteroids and ‘as needed' inhaled short acting beta-2-agonist or patients already adequately controlled on both inhaled corticosteroid and long-acting beta-2-agonist. 
KLINIČNI PODATKI 4.1 Terapevtske indikacije Seretide je indiciran za redno zdravljenje astme, kadar je primerna uporaba kombiniranega zdravila (dolgodelujočega agonista beta 2 in inhaliranega kortikosteroida): pri bolnikih, nezadostno urejenih z inhaliranimi kortikosteroidi in inhaliranim kratkodelujočim agonistom beta-2, uporabljanim "po potrebi",
3705 LZ Zeist 
Huis ter Heideweg 62, 3705 LZ Zeist, Nizozemska
D-40789 Monheim Germany atmadisc mite DosierAerosol FCKW-frei 25 µg/50 µg Druckgasinhalation, Suspension 
Alfred-Nobel-Str. 10 D-40789 Monheim, Nemčija atmadisc mite DosierAerosol FCKW-frei 25 µg/50 µg Druckgasinhalation, Suspension
D-40789 Monheim Germany atmadisc Dosier-Aerosol FCKW-frei 25 µg/125 µg Druckgasinhalation, Suspension 
Alfred-Nobel-Str. 10 D-40789 Monheim, Nemčija atmadisc Dosier-Aerosol FCKW-frei 25 µg/125 µg Druckgasinhalation, Suspension
Very rarely side effects may occur if you have taken high doses of Seretide for a long time and you stop or reduce your dose suddenly. 
Če ste dolgo uporabljali velike odmerke Seretida, pa ga nenadoma nehate uporabljati ali močno zmanjšate odmerek, se lahko v zelo redkih primerih pojavijo neželeni učinki.
What Seretide contains - The active substance(s) are 25 micrograms salmeterol (as xinafoate) and 50, 125 or 250 
- Zdravilni učinkovini sta 25 mikrogramov salmeterola (kot ksinafoata) in 50, 125 ali 250
Box 24 FIN-02231, Espoo Finland 
GlaxoSmithKline Oy, Piispansilta 9A, P.O. Box 24, FIN-02231 Espoo, Finska
To remove the mouthpiece cover, hold the sides of the inhaler with your thumb and forefinger, squeeze the cover gently and pull apart. 
Za odstranitev pokrovčka ustnika primite inhalator ob straneh s palcem in kazalcem,
D-40789 Monheim Germany atmadisc forte DosierAerosol FCKW-frei 25 µg/250 µg Druckgasinhalation, Suspension 
Alfred-Nobel-Str. 10 D-40789 Monheim, Nemčija atmadisc forte DosierAerosol FCKW-frei 25 µg/250 µg
You should ask your doctor for advice before taking Seretide whilst you are pregnant or breastfeeding. 
Če ste noseči ali dojite, se pred uporabo Seretida posvetujte z zdravnikom.
Seretide 25/50 micrograms strength is not appropriate in adults and children with severe asthma; it is recommended to establish the appropriate dosage of inhaled corticosteroid before any fixed combination can be used in patients with severe asthma. 
Pri bolnikih s hudo astmo je pred uvedbo katere koli fiksne kombinacije priporočljivo določiti ustrezni odmerek inhalacijskega kortikosteroida.
A short term trial of Seretide may be considered as initial maintenance therapy in adults or adolescents with moderate persistent asthma (defined as patients with daily symptoms, daily rescue use and moderate to severe airflow limitation) for whom rapid control of asthma is essential. 
Pri bolnikih z zmerno, persistentno astmo (tj. z vsakodnevnimi simptomi, vsakodnevno uporabo olajševalnega zdravila in zmerno do hudo obstrukcijo zračnega pretoka), ki bi jim koristilo hitro obvladanje astme, je mogoče poskusiti z uvodnim 12-tedenskim vzdrževalnim zdravljenjem s Seretidom.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION 
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM [Izpolni država članica]
Seretide Evohaler and associated names (see Annex I) 25/250 microgram/dose pressurised inhalation, suspension. 
Seretide Evohaler in z njim povezana imena (glejte Dodatek I) 25/250 mikrogramov/odmerek, inhalacijska suspenzija pod tlakom.
Seretide Evohaler and associated names (see Annex I) 25/125 microgram/dose pressurised inhalation, suspension [See Annex I - To be completed nationally] 
Seretide Evohaler in povezana imena (Glejte Dodatek I) 25/125 mikrogramov/odmerek, inhalacijska suspenzija pod tlakom [Glejte Dodatek I - Izpolni država članica]
Seretide Evohaler and associated names (see Annex I) 25/50 microgram/dose pressurised inhalation, suspension [See Annex I - To be completed nationally] 
Seretide Evohaler in povezana imena (Glejte Dodatek I) 25/50 mikrogramov/odmerek, inhalacijska suspenzija pod tlakom [Glejte Dodatek I - Izpolni država članica]
Seretide Evohaler and associated names (see Annex I) 25/125 microgram/dose pressurised inhalation, suspension. 
Seretide Evohaler in z njim povezana imena (glejte Dodatek I) 25/125 mikrogramov/odmerek, inhalacijska suspenzija pod tlakom.
Seretide Evohaler and associated names (see Annex I) 25/250 microgram/dose pressurised inhalation, suspension [See Annex I - To be completed nationally] 
Seretide Evohaler in povezana imena (Glejte Dodatek I) 25/250 mikrogramov/odmerek, inhalacijska suspenzija pod tlakom [Glejte Dodatek I - Izpolni država članica]
Seretide Evohaler and associated names (see Annex I) 25/50 microgram/dose pressurised inhalation, suspension. 
Seretide Evohaler in z njim povezana imena (glejte Dodatek I) 25/50 mikrogramov/odmerek, inhalacijska suspenzija pod tlakom.
ANNEX III 
Dublin 16
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER [See Annex I - To be completed nationally] 
IMETNIK DOVOLJENJA ZA PROMET [Glejte dodatek I - Izpolni država članica] {Ime in naslov} {tel.} {faks} {e-pošta}
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 120 puffs 
VSEBNOST PO TEŽI VOLUMNU ALI ENOTI [Izpolni država članica]
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
E14E14E1430 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
The European Commission granted a marketing authorisation valid throughout the European Union for Xiapex on 28 February 2011. 
Evropska komisija je dovoljenje za promet z zdravilom Xiapex, veljavno po vsej Evropski uniji, izdala 28. februarja 2011.
This weakens and disrupts the cord or plaque. 
To oslabi in prekine vozlič ali plak.
Injection site reactions were very common, occurring in the vast majority of patients. 
Reakcije na mestu injiciranja so bile zelo pogoste in so se pojavile pri veliki večini bolnikov.
What measures are being taken to ensure the safe and effective use of Xiapex? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Xiapex?
The full EPAR for Xiapex can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Xiapex je na voljo na spletni strani agencije ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
This is a summary of the European public assessment report (EPAR) for Xiapex. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Xiapex.
Other information about Xiapex 
Druge informacije o zdravilu Xiapex
The patients were treated with three injections and their hands were examined three months after the last injection to see how much the finger joints could be straightened out. 
Bolnike so zdravili s tremi injekcijami, njihove dlani pa so nato pregledali tri mesece po zadnjem injiciranju, da bi ugotovili, koliko se lahko sklepi prstov iztegnejo.
Dupuytren's contracture is a condition where one or more fingers are bent forwards toward the palm and cannot be fully straightened. 
Dupuytrenova kontraktura je bolezen, pri kateri se en ali več prstov upogne naprej proti dlani in jih ni mogoče popolnoma iztegniti.
The most common side effects seen with Xiapex were local injection site reactions such as swelling, bruising, bleeding and pain. 
Najpogostejši neželeni učinki, opaženi pri uporabi zdravila Xiapex, so lokalne reakcije na mestu injiciranja, kot so otekanje, modrice, krvavitve in bolečina.
A risk management plan has been developed to ensure that Xiapex is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Xiapex je bil pripravljen načrt obvladovanja tveganj.
The main measure of effectiveness was the proportion of patients whose main affected joint could be straightened so that it was bent forwards by no more than 5 degrees. 
Glavno merilo učinkovitosti je bil delež bolnikov, pri katerih se je glavni prizadeti sklep lahko iztegnil tako, da ni bil upognjen naprej za več kot 5 stopinj.
Among patients who completed the first study, 64% (130 out of 203) of those receiving Xiapex could straighten their fingers to an angle of 5 degrees or less compared with 7% (7 out of 103) of patients receiving placebo. 
Med bolniki, ki so zaključili prvo študijo, je 64 % (130 od 203) tistih, ki so prejemali zdravilo Xiapex, prste lahko iztegnilo do kota 5 stopinj ali manj v primerjavi s 7 % (7 od 103) bolnikov, ki so prejemali placebo.
The CHMP decided that Xiapex's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Xiapex večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
These reactions were mostly mild to moderate in severity and generally subsided within one to two weeks. 
Večinoma so bile blage do zmerne in so običajno izzvenele v enem do dveh tednih.
If injection and finger extension have not brought about a satisfactory response, the procedure may be repeated at monthly intervals up to a maximum of 3 injections per cord. 
Če po enem injiciranju in iztegovanju prsta ni zadovoljivega odgovora, se postopek lahko ponovi v mesečnih razmikih do največ treh injiciranj na posamezni vozlič.
What benefit has Xiapex shown during the studies? 
Kakšne koristi je zdravilo Xiapex izkazalo med študijami?
For more information on the use of Xiapex, including instructions on finger extension and penile modeling procedures, see the summary of product characteristics (also part of the EPAR). 
Za več informacij o uporabi zdravila Xiapex, vključno z navodili za iztegovanje prstov in postopke oblikovanja penisa, glejte povzetek glavnih značilnosti zdravila (ki je prav tako del EPAR).
Around 24 hours after the injection, the finger can then be straightened by the doctor, by performing a ‘finger extension procedure' whereby it is stretched out for around 10 to 20 seconds to help disrupt the cord. 
Približno 24 ur po injiciranju lahko zdravnik iztegne prst z izvajanjem postopka iztegovanja prstov, pri čemer prst iztegne za približno 10 do 20 sekund, da se pospeši prekinitev vozliča.
Patients should subsequently continue modeling procedures daily at home as instructed for the rest of the cycle. 
Bolniki morajo nato do konca cikla postopke oblikovanja vsak dan izvajati doma v skladu z navodili.
The company must carry out an educational programme for doctors on the correct use and the potential side effects associated with the medicine. 
Izvesti mora tudi izobraževalne programe za zdravnike o pravilni uporabi zdravila in možnih neželenih učinkih, povezanih z njim.
In each cycle, the dose of Xiapex is injected into the plaque causing the deformity followed by a second injection given 1 to 3 days after the first. 
V vsakem ciklu se odmerek zdravila Xiapex injicira v plak, ki povzroča deformacijo, čemur sledi drugi odmerek, ki se injicira od enega do treh dni po prvem.
Xiapex contains a mixture of two ‘collagenases', enzymes that break up collagen. 
Zdravilo Xiapex vsebuje mešanico dveh kolagenaz, tj. encimov, ki razgrajujejo kolagen.
Patients received up to 4 treatment cycles, each involving two injections and subsequent modeling procedures, and the effects were measured on follow-up after 1 year. 
Bolniki so prejeli do štiri cikle zdravljenja, od katerih je vsak vključeval dve injiciranji in kasnejše postopke oblikovanja penisa, učinke pa so izmerili na kontrolnem pregledu po enem letu.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Xiapex. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
For patients with Peyronie's disease, Xiapex is given for up to 4 treatment cycles each lasting about 6 weeks. 
Bolnikom s Peyroniejevo boleznijo se zdravilo Xiapex daje največ štiri cikle zdravljenja, od katerih vsak traja približno šest tednov.
Peyronie's disease is a condition in which men develop plaques of fibrous, scar-like tissue in their penis, causing it to become abnormally curved, and sometimes leading to pain or difficulty in sexual intercourse. 
Peyroniejeva bolezen je bolezen, pri kateri se pri moškem pojavijo plaki v obliki fibroznega brazgotinastega tkiva na penisu, ki se zaradi tega nenormalno ukrivi, kar včasih povzroči bolečine ali težave pri spolnem odnosu.
For more information about treatment with Xiapex, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Xiapex preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The main measures of effectiveness were the reduction in the abnormal curvature of the penis and the extent to which the condition was bothersome to the patient. 
Glavni merili učinkovitosti sta bili zmanjšanje nenormalne ukrivljenosti penisa in ocena, kako moteča je bila bolezen za bolnika.
For Peyronie's disease, Xiapex was compared with placebo in two further studies involving 832 men. 
Pri Peyroniejevi bolezni so zdravilo Xiapex primerjali s placebom v dveh dodatnih študijah, v katerih je sodelovalo 832 moških.
Xiapex was also more effective than placebo in treating Peyronie's disease, producing a 38% and 31% improvement in abnormal curvature in the two studies, compared with 21% and 15% respectively for placebo. 
Zdravilo Xiapex je bilo učinkovitejše od placeba tudi pri zdravljenju Peyroniejeve bolezni, saj je v obeh študijah izboljšalo nenormalno ukrivljenost za 38 % oziroma 31 % v primerjavi z 21 % oziroma 15 % pri uporabi placeba.
What is the risk associated with Xiapex? 
Kakšna tveganja so povezana z zdravilom Xiapex?
For the full list of all side effects and restrictions with Xiapex, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Xiapex glejte navodilo za uporabo.
The cords in the palm of patients with Dupuytren's contracture and the plaques in Peyronie's disease are made of fibres of a protein called collagen. 
Vozliči v dlani bolnikov z Dupuytrenovo kontrakturo in plaki pri Peyroniejevi bolezni so iz vlaken beljakovine, imenovane kolagen.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Xiapex, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
Xiapex was compared with placebo (a dummy treatment) in two main studies involving a total of 374 adult patients with Dupuytren's contracture. 
Zdravilo Xiapex so primerjali s placebom (zdravilom brez zdravilne učinkovine) v dveh glavnih študijah, v katerih je sodelovalo skupno 374 odraslih bolnikov z Dupuytrenovo kontrakturo.
The collagenases in Xiapex are extracted from the bacterium Clostridium histolyticum. 
Kolagenazi v zdravilu Xiapex sta pridobljeni iz bakterije Clostridium histolyticum.
Xiapex is used to treat Dupuytren's contracture and Peyronie's disease in adults. 
Zdravilo Xiapex se uporablja za zdravljenje Dupuytrenove kontrakture in Peyroniejeve bolezni pri odraslih.